Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
Type:
Grant
Filed:
February 4, 1994
Date of Patent:
April 14, 1998
Assignee:
G. D. Searle & Co.
Inventors:
S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
Abstract: The current invention discloses novel amidine derivatives with nitric oxide donating property that can inhibit platelet aggregation and promote vasodilation in a single compound.
Type:
Grant
Filed:
May 15, 1995
Date of Patent:
October 7, 1997
Assignee:
G.D. Searle & Co.
Inventors:
Mark G. Currie, Foe S. Tjoeng, Mark E. Zupec
© 2026 Justia
